The final scorecard for med-tech IPOs in 2019 shows that Lake Forest, Calif.-based Inmode Ltd. performed the best since its August debut, while San Diego-based Guardion Health Sciences Inc. lost the most stock value during the year.

New gene therapy treatments could add $45 billion to the cost of health care over the next five years, according to a new report from CVS Health Corp., of Woonsocket, R.I. While the number is staggering, without knowing the price of the currently unapproved therapies, how many patients will seek treatment and the likelihood of approval, the pharmacy benefit manager's estimate is basically an educated guess.

The top 10 biopharma stock gainers and losers for the week.

Completed biopharma M&As, including: Astellas, Cambrex, Castle Creek, Dendrimer, Effepharm, Fibrocell, Gemphire, Immunovant, J&J, Kyowa, Neurobo, Permira, Roche, Spark, Taris, Xyphos